[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100378723":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":41,"centralContacts":46,"locations":51,"responsibleParty":75,"collaborators":78,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":40,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":40,"enrollmentInfo":91,"targetDuration":40,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":40,"overallStatus":53,"whyStopped":40,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Rutgers, The State University of New Jersey","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort I (loratadine)","EXPERIMENTAL","Beginning 5 days before the first dose of standard of care filgrastim, patients receive loratadine PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.",[13,14],"Drug: Loratadine","Other: Questionnaire Administration",{"label":16,"type":17,"description":18,"interventionNames":19},"Cohort II (placebo)","PLACEBO_COMPARATOR","Beginning 5 days before the first dose of standard of care filgrastim, patients receive placebo PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.",[20,14],"Other: Placebo",[22,29,36],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Loratadine","Given PO",[9],[28],"Claritin",{"type":6,"name":30,"description":25,"armGroupLabels":31,"otherNames":32},"Placebo",[16],[33,34,35],"placebo therapy","PLCB","sham therapy",{"type":6,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Questionnaire Administration","Ancillary studies",[9,16],null,[42],{"name":43,"affiliation":44,"role":45},"Mansi R. Shah, MD","Rutgers Cancer Institute of New Jersey","PRINCIPAL_INVESTIGATOR",[47],{"name":43,"role":48,"phone":49,"phoneExt":40,"email":50},"CONTACT","732-235-4439","shahmr@cinj.rutgers.edu",[52,69],{"facility":44,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"RECRUITING","New Brunswick","New Jersey","08903","United States","US",{"type":60,"coordinates":61},"Point",[62,63],-74.45182,40.48622,{"lat":63,"lon":62},[66,67],{"name":43,"role":48,"phone":49,"phoneExt":40,"email":50},{"name":68,"role":45,"phone":40,"phoneExt":40,"email":40},"Mansi Shah",{"facility":70,"status":71,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":72,"geoPoint":74,"contacts":40},"RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick","NOT_YET_RECRUITING",{"type":60,"coordinates":73},[62,63],{"lat":63,"lon":62},{"type":45,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":44,"oldNameTitle":40,"oldOrganization":40},"Mansi Shah, MD","Assistant Professor of Medicine",[79],{"name":80,"class":81},"National Cancer Institute (NCI)","NIH","100378723","early-phase-1-loratadine-for-the-reduction-of-g-csf-induced-bone-pain-in-patients-with-multiple-myeloma-undergoing-stem-cell-mobilization-100378723",false,"NCT04211259","Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization","The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization","Inclusion Criteria:\n\n* Patient must be able to provide informed consent\n* Patients with confirmed diagnosis of multiple myeloma\n* Able to swallow and retain oral medication\n* All ethnic groups are eligible\n\nExclusion Criteria:\n\n* Non-English speaking person\n* Patients undergoing haploidentical allogeneic hematopoietic stem cell transplant\n* Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds\n* Any medical complications or conditions that would, in the investigator's judgement, interfere with full participation in the study\n* On therapeutic dose of aspirin (doses greater than 81 mg) within 7 days prior to the start of the study","ALL","18 Years",{"count":92,"type":93},70,"ESTIMATED","INTERVENTIONAL",[96],"EARLY_PHASE1","This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.",[99],"Plasma Cell Myeloma","2026-05-26",{"date":102,"type":103},"2026-05-29","ACTUAL",{"date":105,"type":103},"2022-04-18",{"date":107,"type":93},"2027-06-30",{"name":5,"class":6},2]